Literature DB >> 8070021

Teniposide: overview of its therapeutic potential in adult cancers.

F M Muggia1.   

Abstract

Teniposide was introduced into clinical trials prior to etoposide, but its role was not defined because interest shifted early on to etoposide. However, long-term encouraging results obtained in acute leukemia treated with teniposide have rekindled interest in this compound. In addition to pharmacokinetic differences, teniposide has greater CNS penetrance and is more lipophilic. Its greater potency is related to enhanced intracellular uptake. Although its antitumor spectrum of activity appears to be very similar to that of etoposide, a search for some differences might prove instructive.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070021     DOI: 10.1007/bf00684876

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  55 in total

1.  Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells.

Authors:  J D Loike; S B Horwitz
Journal:  Biochemistry       Date:  1976-12-14       Impact factor: 3.162

2.  Proceedings: 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms.

Authors:  B D Sklansky; R S Mann-Kaplan; A F Reynolds; M L Rosenblum; M D Walker
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

3.  The epipodophyllotoxin VP16-213 in combination chemotherapy for adults with acute nonlymphoblastic leukaemia.

Authors:  P Jacobs
Journal:  Haematol Blood Transfus       Date:  1985

4.  Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners.

Authors:  J D Loike; C F Brewer; H Sternlicht; W J Gensler; S B Horwitz
Journal:  Cancer Res       Date:  1978-09       Impact factor: 12.701

5.  Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.

Authors:  D Kerrigan; Y Pommier; K W Kohn
Journal:  NCI Monogr       Date:  1987

6.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

Authors:  M L Slevin; P I Clark; S P Joel; S Malik; R J Osborne; W M Gregory; D G Lowe; R H Reznek; P F Wrigley
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

7.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.

Authors:  W Ross; T Rowe; B Glisson; J Yalowich; L Liu
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

8.  [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].

Authors:  R P Jankowski; H Vahrson
Journal:  Med Klin       Date:  1977-12-09

9.  Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC).

Authors:  T Cerny; A Pedrazzini; R A Joss; K W Brunner
Journal:  Eur J Cancer Clin Oncol       Date:  1988-11

10.  Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage.

Authors:  T Rowe; G Kupfer; W Ross
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

View more
  3 in total

1.  Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor.

Authors:  Jingjia Yan; Jiaxiao Sun; Zhiyuan Zeng
Journal:  Inflammopharmacology       Date:  2017-08-20       Impact factor: 4.473

2.  Long-term remission of subcutaneous panniculitis-like T-cell lymphoma with central nervous system involvement: A case report.

Authors:  Yajuan Qiu; Dandan Zhang; Mingzhi Zhang
Journal:  Oncol Lett       Date:  2016-05-26       Impact factor: 2.967

3.  Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma.

Authors:  Yi-Xia Wang; Yan Huang; Xiao-Ping Xu; Bo-Bin Chen; Zhi-Guang Lin; Yan Ma; Tian-Ling Ding; Qian Wang
Journal:  Oncol Lett       Date:  2020-01-22       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.